Please login to the form below

Not currently logged in
Email:
Password:

Teva's vice chair steps down

Amir Elstein to take over from Moshe Many
Teva Amir Elstein

Teva faces yet more senior changes as Prof Moshe Many announced his intention to step down as vice chairman at the beginning of next year.

According to Teva, Prof Many is leaving his position for “personal reasons” and will be replaced by board director Amir Elstein. This change will take place on January 1, 2014.

It is second major change at the top for Teva in recent months after the company announced its president and CEO Jeremy Levin was stepping down after just 18 months in the position.

Commenting on Prof Many's decision to step down, Teva's chairman Dr Phillip Frost said: "I would like to thank Prof Many for his outstanding service as vice chairman and wish Amir success in continuing Moshe's good work."

16th December 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics